Nuvalent (NASDAQ:NUVL) Announces Quarterly Earnings Results

Nuvalent (NASDAQ:NUVL - Get Free Report) posted its quarterly earnings data on Thursday. The company reported ($1.39) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.35) by ($0.04), FiscalAI reports. During the same period in the previous year, the business posted ($1.18) earnings per share.

Nuvalent Price Performance

NASDAQ:NUVL traded down $1.86 during mid-day trading on Thursday, reaching $102.40. The stock had a trading volume of 593,731 shares, compared to its average volume of 566,173. The business's 50 day moving average is $101.99 and its 200 day moving average is $102.28. Nuvalent has a fifty-two week low of $63.56 and a fifty-two week high of $113.01. The stock has a market cap of $8.05 billion, a P/E ratio of -17.50 and a beta of 1.15.

Wall Street Analyst Weigh In

A number of analysts have recently issued reports on NUVL shares. Wells Fargo & Company started coverage on shares of Nuvalent in a research report on Monday, March 30th. They issued an "overweight" rating and a $116.00 price target for the company. Weiss Ratings reissued a "sell (d-)" rating on shares of Nuvalent in a research report on Tuesday, April 21st. HC Wainwright reissued a "buy" rating and issued a $155.00 price target on shares of Nuvalent in a research report on Tuesday, April 21st. Wedbush reissued an "outperform" rating and issued a $125.00 price target on shares of Nuvalent in a research report on Wednesday, April 8th. Finally, Cantor Fitzgerald upped their price target on shares of Nuvalent from $135.00 to $140.00 and gave the stock an "overweight" rating in a research note on Friday, February 27th. Sixteen analysts have rated the stock with a Buy rating and one has given a Sell rating to the company's stock. According to MarketBeat, Nuvalent presently has a consensus rating of "Moderate Buy" and a consensus target price of $137.25.

Insider Transactions at Nuvalent

In related news, insider Deborah Ann Miller sold 5,500 shares of the stock in a transaction that occurred on Thursday, April 30th. The stock was sold at an average price of $99.22, for a total value of $545,710.00. Following the transaction, the insider owned 59,634 shares in the company, valued at approximately $5,916,885.48. This represents a 8.44% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, CEO James Richard Porter sold 30,000 shares of the stock in a transaction that occurred on Monday, May 4th. The stock was sold at an average price of $101.69, for a total value of $3,050,700.00. Following the completion of the transaction, the chief executive officer owned 324,879 shares in the company, valued at $33,036,945.51. This represents a 8.45% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last three months, insiders have sold 80,023 shares of company stock worth $8,235,217. Corporate insiders own 10.20% of the company's stock.

Hedge Funds Weigh In On Nuvalent

Hedge funds have recently added to or reduced their stakes in the company. Prudential Financial Inc. acquired a new position in Nuvalent in the second quarter worth approximately $412,000. E Fund Management Co. Ltd. grew its holdings in Nuvalent by 12.9% during the second quarter. E Fund Management Co. Ltd. now owns 5,401 shares of the company's stock valued at $412,000 after purchasing an additional 616 shares during the last quarter. Xponance LLC grew its holdings in Nuvalent by 17.3% during the fourth quarter. Xponance LLC now owns 3,965 shares of the company's stock valued at $399,000 after purchasing an additional 585 shares during the last quarter. CIBC Bancorp USA Inc. acquired a new position in Nuvalent during the third quarter valued at approximately $396,000. Finally, Freestone Grove Partners LP acquired a new position in Nuvalent during the third quarter valued at approximately $342,000. Institutional investors and hedge funds own 97.26% of the company's stock.

Nuvalent Company Profile

Nuvalent, Inc NASDAQ: NUVL is a clinical-stage precision oncology company focused on the discovery, development and commercialization of targeted therapies for patients with genetically defined cancers. Founded in 2019 and headquartered in San Diego, California, Nuvalent applies structure-guided drug design to develop small molecule inhibitors that address key oncogenic drivers. The company's research platform integrates insights from cancer biology, medicinal chemistry and translational science to create therapies with differentiated selectivity and potency against validated targets.

Nuvalent's lead pipeline candidates include NVL-520, a highly selective RET inhibitor designed to minimize off-target effects, and NVL-655, a potent covalent inhibitor targeting KRAS G12D mutations.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.